These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 25870079)

  • 1. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R; Lu N; Campochiaro PA
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
    Domalpally A; Ip MS; Ehrlich JS
    Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
    Kim M; Lee P; Kim Y; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
    Sardana A; Singh K; Singh A; Singh VK
    Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.
    Channa R; Sophie R; Khwaja AA; Do DV; Hafiz G; Nguyen QD; Campochiaro PA;
    Eye (Lond); 2014 Mar; 28(3):269-78. PubMed ID: 24263379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
    Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
    Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema.
    Srinivas S; Verma A; Nittala MG; Alagorie AR; Nassisi M; Gasperini J; Sadda SR
    Am J Ophthalmol; 2020 Mar; 211():183-190. PubMed ID: 31758926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractive changes after pharmacologic resolution of diabetic macular edema.
    Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
    Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials.
    Bansal AS; Khurana RN; Wieland MR; Wang PW; Van Everen SA; Tuomi L
    Ophthalmology; 2015 Aug; 122(8):1573-9. PubMed ID: 26050541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.